Medical Condition News

RSS

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Naloxegol holds hope for opioid-induced constipation

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

5 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It's the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA).

From COOK MEDICAL INC. 5 Jun 2014

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Researchers at Shepherd Center are studying whether stimulating the brain before rehabilitation could yield greater gains in motor function for people recovering from stroke.

5 Jun 2014

Many heroin users transitioned from prescription opioids, finds study

A research paper published in the May 28, 2014 issue of JAMA Psychiatry a paper entitled "The Changing Face of Heroin Use in the United States A Retrospective Analysis of the Past 50 Years" concluded that heroin abuse has left low-income urban areas and has become prevalent in more affluent suburbs and rural areas with mostly white populations.

5 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.

5 Jun 2014

Novel diagnostic tool helps differentiate between dementia diseases

A new diagnostic tool helps clinicians to differentiate between Alzheimer's disease, frontotemporal dementia and mild cognitive impairment. Presented in the doctoral thesis of MD Miguel ángel Muñoz Ruiz at the University of Eastern Finland, the new method consists of a Disease State Index combining data from multiple sources, and of a Disease State Fingerprint showing the findings in a visual format.

5 Jun 2014

Affymetrix, BioDiscovery launch new analysis software for cancer research

Affymetrix and BioDiscovery, Inc. today announced the launch of a new analysis software, Nexus Copy Number for Affymetrix, which is specifically for data generated by Affymetrix' genetic analysis platforms in cancer research, including CytoScan Cytogenetics Suite and OncoScan FFPE Assay Kit.

5 Jun 2014

Palliative support services help caregivers of patients with advanced cancer

Dartmouth researchers have found that those caring for patients with advanced cancer experienced reduced depression and felt less burdened by caregiving tasks when palliative support services were offered soon after the patient's diagnosis.

5 Jun 2014

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers.

5 Jun 2014

Medical Condition News

MolecularHealth launches innovative oncology program for employers

Naloxegol holds hope for opioid-induced constipation

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Many heroin users transitioned from prescription opioids, finds study

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

Novel diagnostic tool helps differentiate between dementia diseases

Affymetrix, BioDiscovery launch new analysis software for cancer research

Palliative support services help caregivers of patients with advanced cancer

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

Variety of lifestyle and health factors increase memory complaints among young adults

Whole genome sequencing reveals severe intellectual disability in patients

Geoff Keller Group of MHAUS hosts fundraising event to promote MH awareness

Macrophages present in shed endometrium may contribute to lesion formation, shows study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News